What is Seraxis?
Founded in 2013 and operating from Germantown, Maryland, Seraxis is dedicated to addressing the challenges of Type 1 diabetes through advanced cell manufacturing. The company possesses a proprietary cell line and technology designed to produce human pancreas cells, known as pancreatic islets, which are crucial for insulin production. These islets are engineered to be transplant-ready and are protected from immune system rejection by their SeraGraft device, offering a potential pathway to a functional cure for individuals requiring insulin therapy.
How much funding has Seraxis raised?
Seraxis has raised a total of $40.1M across 2 funding rounds:
Debt
$87K
Series C
$40M
Debt (2021): $87K with participation from PPP
Series C (2021): $40M led by Frazier Healthcare Partners, Eli Lilly and Company, Polaris Partners, and JDRF T1D Fund
Key Investors in Seraxis
Frazier Healthcare Partners
Frazier Healthcare Partners is a prominent venture capital firm that invests in healthcare companies. Their focus spans across various stages of development, from early-stage to growth-stage, with a particular interest in biopharmaceuticals and medical devices.
Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical giant with a strong commitment to discovering, developing, and commercializing innovative medicines. They have a significant presence in diabetes care and are known for their extensive research and development efforts.
Polaris Partners
Polaris Partners is a venture capital firm that actively supports companies in the biotechnology and healthcare industries. They provide strategic guidance and capital to help entrepreneurs build and scale their ventures, focusing on transformative solutions.
What's next for Seraxis?
The recent major strategic investment signals a pivotal growth phase for Seraxis, likely enabling the company to advance its clinical development pipeline and scale its manufacturing capabilities. This capital infusion is expected to accelerate the path toward regulatory approval and commercialization of its innovative islet cell therapy. The company's focus on a critical unmet need in diabetes treatment positions it for substantial impact and future expansion within the regenerative medicine sector.
See full Seraxis company page
